Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2022

Aug 9, 2022

30718_dirs_2022-08-09_b03e6570-4417-4452-ad35-2ca12946ccac.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-08-07

Reporting Person: Kelderman Kim (Pres. Diagnostics & Genom)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-08-07 Common Stock M 2363 Acquired 4352 Direct
2022-08-07 Common Stock F 1214 $382.97 Disposed 3138 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-08-07 Restricted Stock Units $ M 2363 Disposed Common Stock (2363) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $150.7800 2025-05-01 Common Stock (7511) 7511 Direct
Stock Option (Right to Buy) $177.3200 2025-08-08 Common Stock (12044) 12044 Direct
Stock Option (Right to Buy) $177.3200 2025-08-08 Common Stock (9033) 9033 Direct
Stock Option (Right to Buy) $190.4100 2026-08-07 Common Stock (11961) 11961 Direct
Stock Option (Right to Buy) $190.4100 2026-08-07 Common Stock (15948) 15948 Direct
Restricted Stock Units $ Common Stock (2015) 2015 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8991) 8991 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (11988) 11988 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Restricted Stock Units $ Common Stock (1245) 1245 Direct
Stock Option (Right to Buy) $481.8200 2028-08-06 Common stock (6486) 6486 Direct
Stock Option (Right to Buy) $481.8200 2028-08-06 Common Stock (4864) 4864 Direct

Footnotes

F1: Fully exercisable.

F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F3: On 8/7/2022, the Board of Directors certified vesting of 2,363 performance RSUs.

F4: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.

F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.

F7: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F8: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F10: Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.